PITTSBURGH, June 24, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Roger Graham as president of Mylan Specialty. Graham will report to Tony Mauro, president of Mylan North America.
Mylan CEO Heather Bresch commented, "Roger's deep brand pharmaceutical industry experience, entrepreneurial mind-set and goal-oriented leadership make him the ideal candidate to lead Mylan Specialty as we continue to expand this important business. We remain very excited about the growth prospects of the Specialty business and are confident that Roger will bring immediate value to our entire North American organization and help accelerate achievement of our ambitions for Mylan Specialty."
Graham joins Mylan from Advandx, a private developer of in-vitro diagnostic tests in the infectious disease space. He was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets.
Prior to that, Graham spent nearly a decade in executive-level marketing and sales positions at three brand pharmaceutical firms, Auxilium Pharmaceuticals, Adolor Corporation and Yamanouchi Pharma America, where he established, rebuilt and/or expanded U.S. commercial operations.
Earlier, Graham worked at Ortho McNeil, a division of Johnson & Johnson (J&J), where he was vice president of the company's $2 billion anti-infective, analgesia and urology franchise, and its 2,300 primary care and hospital sales and marketing associates. Graham also built Ortho McNeil's $500 million neuroscience and metabolic franchise via the launch and life cycle development of Topamax®.
Graham previously served as director of Marketing for Roche's CNS, pain and dermatology franchises.
|SOURCE Mylan Inc.|
Copyright©2012 PR Newswire.
All rights reserved